Thursday, March 26, 2020 - 8:01am
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
- DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
The issuer is solely responsible for the content of this announcement.
- Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
- Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
- The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.